The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve‐week randomized, double‐blind, placebo‐controlled trial followed by an open‐label extension up to week fifty‐two
Abstract
Objective: To evaluate the efficacy and safety of the tumor necrosis factor (TNF) antagonist adalimumab in patients with axial spondylarthritis (SpA) without radiographically defined sacroiliitis refractory to conventional treatment. Methods: Patients with active axial SpA (n = 46) were randomized to receive placebo or adalimumab at a dosage of 40 mg subcutaneously every other week for 12 weeks, followed by an open‐label extension that continued up to week 52. The diagnosis of axial SpA required the presence of 3 of 6 diagnostic criteria, including 2 of the following 3 criteria: inflammatory back pain, HLA–B27 positivity, or acute inflammation of the spine or sacroiliac joints on magnetic resonance imaging, in the absence of radiographic evidence of sacroiliitis. The primary end point was a 40% response according to the improvement criteria of the Assessment of SpondyloArthritis international Society (ASAS40). Results: All 46 patients (22 receiving adalimumab and 24 receiving placebo) completed the 12‐week trial; 38 patients completed the extension period to week 52. At week 12, an ASAS40 response was achieved by 54.5% of the adalimumab‐treated patients, as compared with 12.5% of the placebo‐treated patients ( P = 0.004). After switching to adalimumab, a similar degree of efficacy was also achieved by the patients who were initially treated with placebo. Efficacy was maintained in all patients until week 52. Young age at study entry and an elevated C‐reactive protein concentration were the best predictors of achieving an ASAS40 response. Serious adverse events occurred in 5 patients, none of which was related to the study drug. Conclusion: Adalimumab is the first TNF antagonist to demonstrate good clinical efficacy and safety in patients with axial SpA without radiographically defined sacroiliitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Evaluation of Diagnostic Criteria for Ankylosing Spondylitis
Linden, S. V. D., Valkenburg, H. A., & Cats, A. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780270401 · Cited by 5,697
Garrett, S., Jenkinson, T., Kennedy, L. G., Whitelock, H., Gaisford, P., & Călin, A. (1994) · PubMed · Cited by 3,241
Dougados, M., Linden, S. V. D., Juhlin, R., Huitfeldt, B., Amor, B., Calin, A., Cats, A., Dijkmans, B., Olivieri, I., Pasero, G., et al. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780341003 · Cited by 2,299
Călin, A., Garrett, S., Whitelock, H., Kennedy, L. G., O'Hea, J., MALLORIE, P. A., & Jenkinson, T. (1994) · PubMed · Cited by 1,834
(2001) · Classic Papers in Rheumatology · doi:10.3109/9780203214237-70 · Cited by 1,833
Russo, J., Trujillo, C. A., Wingerson, D., Decker, K., Ries, R., Wetzler, H., & Roy-Byrne, P. (1998) · Medical Care · doi:10.1097/00005650-199805000-00015 · Cited by 1,308
Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Golder, W., Gromnica-lhle, E., Kellner, H., Krause, A., Schneider, M., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08215-6 · Cited by 1,261
Self-citationDefining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.
Jenkinson, T., MALLORIE, P. A., Whitelock, H., KENNEDY, L. G., Garrett, S. L., & Călin, A. (1994) · PubMed · Cited by 981
Cited by
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
Braun, J., van den Berg, R., Baraliakos, X., Boehm, H., Burgos-Vargas, R., Collantes-Estevez, E., Dagfinrud, H., Dijkmans, B., Dougados, M., Emery, P., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.151027 · Cited by 987
Self-citationAdverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
Dougados, M., & Baeten, D. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60071-8 · Cited by 780
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Self-citationSieper, J., van der Heijde, D., Dougados, M., Mease, P. J., Maksymowych, W. P., Brown, M. A., Arora, V., & Pangan, A. L. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201766 · Cited by 536
Self-citation
Metadata
- Authors
- Haibel, H., Rudwaleit, M., Listing, J., Heldmann, F., Wong, R. L., Kupper, H., Braun, J., & Sieper, J.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2008-06-24
- Volume
- 58
- Issue
- 7
- Pages
- 1981-1991
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2076685991
- Cited by
- 316
- References
- 27
- FWCI
- 15.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve‐week randomized, double‐blind, placebo‐controlled trial followed by an open‐label extension up to week fifty‐two. https://app.cochat.ai/papers/10.1002/art.23606
- The paper
- Haibel, H., Rudwaleit, M., Listing, J., Heldmann, F., Wong, R. L., Kupper, H., Braun, J., & Sieper, J. (2008). Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve‐week randomized, double‐blind, placebo‐controlled trial followed by an open‐label extension up to week fifty‐two. Arthritis & Rheumatism. https://doi.org/10.1002/art.23606
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.